Intra-Cellular Therapies Inc (BSP:I2TC34)
R$ 84.24 0 (0%) Market Cap: 52.81 Bil Enterprise Value: 46.88 Bil PE Ratio: 0 PB Ratio: 7.72 GF Score: 32/100

Intra-Cellular Therapies Inc at RBC Capital Markets Global Healthcare Conference Transcript

May 17, 2023 / 02:30PM GMT
Brian Abrahams
RBC Capital Markets - Analyst

I'm Brian Abrahams, one of the senior biotech analysts here at RBC Capital Markets. Our next presenting company is Intra-Cellular Therapies represented by their CEO, Sharon Mates. Sharon, thanks again for joining us.

Sharon Mates
Intra-Cellular Therapies, Inc. - Founder, Chairman & CEO

Thanks for having me.

Brian Abrahams
RBC Capital Markets - Analyst

So maybe just to kick off on CAPLYTA. I would love to hear more about what you're hearing on the ground from physicians and patients across the different marketed indications with respect to CAPLYTA's profile, overall receptivity, and how they're using the drug in practice.

Sharon Mates
Intra-Cellular Therapies, Inc. - Founder, Chairman & CEO

Sure. So before we start with our Q&A, it's important that I tell you that today, I will be making forward-looking statements under the Private Securities Litigation Reform Act of 1995. Our actual results may differ, and I

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot